GlassScriptPhysician profile
Swaroopa V Bartakke
NPI 1902004005
$3,879.12
in general payments reported to CMS, 2019-2025
35 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $37.57 · 2021: $331 · 2022: $319 · 2023: $1,163 · 2024: $1,081 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $447.90 | 2019-2025 | Omnipod |
| Cequr Corporation | $340.76 | 2023-2025 | Cequr Simplicity |
| Abbott Laboratories | $332.11 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Beta Bionics, INC. | $292.93 | 2023-2024 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $279.14 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals LP | $266.14 | 2019-2022 | |
| Esperion Therapeutics, INC. | $175.87 | 2021-2022 | |
| Corcept Therapeutics | $155.63 | 2021-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.70 | 2019-2024 | Jardiance |
| Pfizer INC. | $127.87 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.70 | 2023-2024 | |
| Radius Health, INC. | $96.63 | 2022-2024 | Tymlos |
| Amneal Pharmaceuticals LLC | $96.15 | 2021-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $89.51 | 2023-2024 | |
| Medtronic, INC. | $84.58 | 2023-2025 | Minimed 780g |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $82.98 | 2024-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $72.28 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amryt Pharma Holdings LTD | $69.39 | 2022-2023 | Mycapssa |
| Ascensia Diabetes Care US INC. | $67.82 | 2023 | |
| Xeris Pharmaceuticals, INC. | $63.02 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $58.68 | 2021-2024 | Tepezza, Repatha |
| Nevro Corp. | $46.66 | 2023 | Senza |
| Hologic Sales and Service, LLC | $46.45 | 2025 | Aptima |
| Mannkind Corporation | $41.74 | 2024 | |
| Inspire Medical Systems, INC. | $38.99 | 2024 | Inspire |
| Kyowa Kirin, INC. | $36.51 | 2023 | |
| Horizon Therapeutics Plc | $35.90 | 2023 | Tepezza |
| Merck Sharp & Dohme LLC | $33.91 | 2019-2022 | |
| Halozyme INC | $22.79 | 2023 | |
| Genzyme Corporation | $19.76 | 2024 | |
| Chiesi USA, INC. | $19.51 | 2024 | Mycapssa |
| Axsome Therapeutics, INC. | $16.58 | 2024 | Sunosi |
| Amphastar Pharmaceuticals, INC. | $16.30 | 2024 | |
| Ascendis Pharma Endocrinology INC | $12.78 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swaroopa Bartakke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.